
    
      The purpose of this study is to confirm the safety of 24 weeks-treatment with the combination
      of tacrolimus + biological agents, and to assess the efficacy using SDAI, CDAI, DAS28-CRP,
      MMP-3, MHAQ in patients with rheumatoid arthritis who have not achieved SDAI remission
      despite of using biological agents for over 8 weeks.
    
  